Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Novartis International (Details)

v3.20.1
Licensing and Other Arrangements - Novartis International (Details)
$ in Thousands
12 Months Ended
Sep. 30, 2015
item
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Licensing and other arrangements          
Revenue from contracts with customers   $ 17,276 $ 5,068    
Novartis International | License Agreement          
Licensing and other arrangements          
Agreement termination prior written notice period 180 days        
Number of performance obligations | item 1        
Upfront payment received         $ 37,000
Revenue from contracts with customers       $ 10,000 $ 37,000
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones   470,000      
Royalty payment period 10 years        
Contract assets   0 0    
Contract liabilities   0 0    
Capitalized contract costs   $ 0 $ 0